Veeva Systems Inc.
In the published model solve dated 2026-Q2, anchored at $276.65, Veeva Systems Inc. (VEEV) is priced for today's economics sustained for ~9.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• Veeva is the software backbone of the drug industry: its filing calls it "the leading provider of industry cloud solutions for the global life sciences industry," spanning the systems pharma companies use to run clinical trials, manage quality, and sell to doctors, with first-quarter revenue of $883 million up 16% and a 45% non-GAAP operating margin [Source: Q1 earnings release, 2026]. • The defining risk is that it serves one industry: the filing states "our revenues are relatively concentrat
Is VEEV overvalued? See what's priced in →
990 institutional managers reported holding VEEV in 13F filings for the quarter ended 2026-03-31. Together they hold about 80% of the company; the top 10 hold 34%. 110 opened new positions that quarter. Held by Vanguard Group, BlackRock, AllianceBernstein, among others. On the short side, 7.5M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (2.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
VEEV's share count grew 6.7% over the past five years even with $226.95M spent on repurchases. It pays no dividend. Cash returned over the past three years: $226.95M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at VEEV over the trailing three years. Absence is a fact about the company, not a signal. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
VEEV's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-06-03 | +21.2% | +1.0% |
| 2023-09-02 | +8.1% | -10.2% |
| 2023-12-08 | -2.8% | +25.5% |
| 2024-03-26 | -1.5% | -12.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
VEEV's latest 8-K filings: 2026-08-26 (items 2.02, 9.01); 2026-08-20 (items 5.02, 9.01); 2026-06-18 (items 5.07, 9.01); 2026-06-03 (items 2.02, 9.01); 2026-04-20 (items 5.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.